Comparing the current results to its competitors, Endra Life Sciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.72 %, recorded in the same quarter.
Endra Life Sciences Inc's Comment on Competition and Industry Peers
The company operates in a competitive market for ultrasound systems, where its market share may be affected if proprietary technologies are used by others or if patents are invalidated. It employs confidentiality agreements to protect trade secrets, though these measures may not fully prevent unauthorized disclosure or independent development by competitors. Regulatory agencies such as the FDA and FTC oversee the advertising and promotion of its products to ensure claims are substantiated and not misleading, with potential enforcement actions that could impact the company's reputation and sales. Competitive factors include new product introductions, industry consolidation, pricing strategies, and technological advancements. Additional influences on competition encompass regulatory approvals, market acceptance, reimbursement availability, customer base growth, operational costs, economic conditions, employee retention, litigation, and access to financing.
November 20, 2025
Innovation in Liver Health: ENDRA Life Sciences TAEUS Device Shows Promising Results ANN ARBOR, Mich. ENDRA Life Sciences Inc. (NASDAQ: NDRA), a trailblazer in the realm of biomarker imaging technologies, is drawing significant attention with its recent advancements in the field of liver health. The company, recognized for its innovative methods in addressing metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), has revealed promising preliminary results from its clinical studies involving the TAEUS Liver device. Promising Results from TAEUS Feasibility Study In an encouraging development, a single-site clinical feasibility study demonstrated t...
November 13, 2025
ENDRA Life Sciences Inc. (NASDAQ: NDRA), based in Ann Arbor, Michigan, is at the forefront of revolutionizing medical imaging technologies for the detection and monitoring of metabolic liver diseases. But the company’s ambition doesn’t end with healthcare technology; they are also strategically embracing the emerging digital asset landscape. This dual focus not only reflects ENDRA’s innovative spirit but also positions the company to capitalize on new opportunities in a rapidly evolving market. A Strategic Move into Digital Assets Recently, ENDRA announced the staking of its holdings in HYPE, the native token of the Hyperliquid ecosystem. This strategic initiative marks a significant step in the compan...
October 23, 2025
ENDRA Life Sciences: A Transformative Shift with New Investments and Regulatory Compliance Boost ENDRA Life Sciences Inc. (NASDAQ: NDRA), based in Ann Arbor, Michigan, has recently undertaken significant steps that could bolster its position in the imaging technology sector and enhance its financial standing. Here, we explore the implications of the company’s latest developments. Key Developments1. Successful Private Placement : ENDRA closed a private investment in public equity (PIPE) financing, securing up to $14.4 million led by a mix of institutional and cryptocurrency investors. This influx of capital is critical for the company as it progresses in the competitive field of medical imaging technolog...
November 23, 2024
In a notable development for the financial health and operational integrity of Endra Life Sciences Inc. (NASDAQ: NDRA), the company recently announced that it has successfully regained compliance with The Nasdaq Stock Market s minimum bid price requirement. This milestone is significant, as it reinforces Endra s commitment to meeting the stringent regulatory standards and market expectations set forth by the Nasdaq Listing Qualifications Department. As of November 21, 2024, Endra received official notification confirming its compliance with Listing Rule 5550(a)(2), thereby solidifying its status on the exchange.Endra Life Sciences, known for its groundbreaking innovations in Thermo Acoustic Enhanced UltraSou...
August 23, 2024
In a recent financial update, ENDRA Life Sciences Inc. (NASDAQ: NDRA) showcased significant strides in its operations and financial health for the second quarter of 2024. The company, based in Ann Arbor, Michigan, is recognized for its innovative Thermo Acoustic Enhanced Ultrasound (TAEUS) technology, which aims to enhance diagnostic imaging.In a Form 10-Q submitted on August 14, 2024, ENDRA reported its financial results for the quarter and the first half of the year, indicating a net borrowing increase of 12.42%. This uptick in borrowing aligns with the company s strategic s; however, it raised questions about its financial sustainability. Contrary to these concerns, ENDRA made notable advancements in its ...
May 20, 2024
ENDRA Life Sciences, a pioneer in Thermo Acoustic Enhanced UltraSound (TAEUS), recently completed a productive pre-submission meeting with the U.S. Food and Drug Administration (FDA) to discuss the clinical trial design of its TAEUS liver device. The meeting aimed to support the company s upcoming U.S. De Novo filing. Prior to the meeting, ENDRA provided the FDA with a comprehensive description of the TAEUS technology.In addition to this update, ENDRA Life Sciences has also revealed its financial results for the fourth quarter and full year of 2023, along with a business update. The company highlighted several significant achievements during the period, including the installation of the first TAEUS system in...
May 14, 2024
Innovative medical technology company ENDRA Life Sciences Inc. (NASDAQ: NDRA) continues to disrupt the healthcare industry with its pioneering Thermo Acoustic Enhanced UltraSound (TAEUS) technology. The company recently reported its financial results for the first quarter of 2024, highlighting significant achievements and advancements. This article delves into the key milestones reached by the company, showcasing the potential of TAEUS and its impact on medical diagnostics.1. Groundbreaking Clinical Evaluation at King s College Hospital in the UKENDRA Life Sciences installed the first TAEUS system at King s College Hospital, a prestigious institution renowned for its excellence in medical research and patien...
March 28, 2024
In the latest financial results and business update, ENDRA Life Sciences Inc., the trailblazer in the Thermo Acoustic Enhanced UltraSound (TAUES) technology, recently released the financial results of the fourth quarter and full December year 2023. The company, which uses the groundbreaking TAUES technology to improve the accessibility, safety, and cost-efficiency of visualizing tissue composition, function, and temperature, has been making significant strides in recent months. Prominent highlights from the fourth quarter of the year and in recent weeks revealed a significant milestone for ENDRA. They announced the successful installation of their first TAEUS system in the UK, specifically at the esteemed Ki...
February 21, 2024
The World Health Organization s recent adoption of the ICD-10 K76.0 code for Non-Alcoholic Fatty Liver Disease (NAFLD) diagnosis has set the stage for significant advancements in liver disease diagnostics. This landmark update reflects the growing recognition of NAFLD s global health impact by insurance providers and healthcare professionals alike. With ENDRAs Thermo Acoustic Enhanced UltraSound (TAEUS) system, we are witnessing a revolutionary breakthrough that promises to dramatically improve NAFLD diagnostics.Uncovering the Rising Awareness:NAFLD has emerged as a silent epidemic in recent years, affecting millions of people worldwide. Previously overshadowed by other liver conditions, the World Health Org...
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Glucotrack Inc's business model is focused on developing and marketing innovative non-invasive glucose monitoring devices for individuals with diabetes.
Sources:
Endra Life Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Endra Life Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
